Sinocelltech Group Ltd (SHA: 688520), a biopharmaceutical company based in China, has announced that it has received clearance from the National Medical Products Administration (NMPA) to initiate a Phase I clinical study for its monoclonal antibody SCTC21C, targeting CD38+ hematological malignant tumors. This development marks a significant step forward in the company’s efforts to address the unmet medical needs in oncology.
Preclinical studies of SCTC21C have demonstrated promising pharmacokinetics and safety profiles for the monoclonal antibody, which specifically targets the CD38 antigen. This antigen is overexpressed in various hematological malignancies, making it a key therapeutic target for the development of novel treatments.- Flcube.com
